32 results on '"Cerhan JH"'
Search Results
2. Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614.
- Author
-
Wefel JS, Deshmukh S, Brown PD, Grosshans DR, Sulman EP, Cerhan JH, Mehta MP, Khuntia D, Shi W, Mishra MV, Suh JH, Laack NN, Chen Y, Curtis AA, Laba JM, Elsayed A, Thakrar A, Pugh SL, and Bruner DW
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Apolipoprotein E4 genetics, Apolipoproteins E genetics, Cognition radiation effects, Cranial Irradiation adverse effects, Genotype, Heterozygote, Proportional Hazards Models, Brain Neoplasms secondary, Brain Neoplasms radiotherapy, Brain Neoplasms genetics, Memantine therapeutic use
- Abstract
Purpose: Whole-brain radiation therapy (WBRT) is a common treatment for brain metastases and is frequently associated with decline in neurocognitive functioning (NCF). The e4 allele of the apolipoprotein E (APOE) gene is associated with increased risk of Alzheimer disease and NCF decline associated with a variety of neurologic diseases and insults. APOE carrier status has not been evaluated as a risk factor for onset time or extent of NCF impairment in patients with brain metastases treated with WBRT., Methods and Materials: NRG/Radiation Therapy Oncology Group 0614 treated adult patients with brain metastases with 37.5 Gy of WBRT (+/- memantine), performed longitudinal NCF testing, and included an optional blood draw for APOE analysis. NCF test results were compared at baseline and over time with mixed-effects models. A cause-specific Cox model for time to NCF failure was performed to assess the effects of treatment arm and APOE carrier status., Results: APOE results were available for 45% of patients (n = 227/508). NCF did not differ by APOE e4 carrier status at baseline. Mixed-effects modeling showed that APOE e4 carriers had worse memory after WBRT compared with APOE e4 noncarriers (Hopkins Verbal Learning Test-Revised total recall [least square mean difference, 0.63; P = .0074], delayed recognition [least square mean difference, 0.75; P = .023]). However, APOE e4 carrier status was not associated with time to NCF failure (hazard ratio, 0.86; 95% CI, 0.60-1.23; P = .40). Memantine delayed the time to NCF failure, regardless of carrier status (hazard ratio, 0.72; 95% CI, 0.52-1.01; P = .054)., Conclusions: APOE e4 carriers with brain metastases exhibited greater decline in learning and memory, executive function, and the Clinical Trial Battery Composite score after treatment with WBRT (+/- memantine), without acceleration of onset of difference in time to NCF failure., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
3. Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study.
- Author
-
Beyer J, Couch R, Ruddy KJ, Zeydan B, Tosakulwong N, Lesnick TG, Novotny PJ, Kohli S, Cerhan JH, Pruthi S, Kantarci K, and Kara F
- Subjects
- Humans, Female, Creatine, Brain pathology, Cognition, Gyrus Cinguli, Choline, Aspartic Acid, Breast Neoplasms pathology
- Abstract
Few proton magnetic resonance spectroscopy studies have explored chemotherapy-related biochemical changes in brain regions. This observational study aimed to longitudinally assess short-term cognitive changes and brain metabolite concentrations in women undergoing chemotherapy for breast cancer. We analyzed 11 women with newly diagnosed stage 1 to 3 breast cancer. Patients were evaluated via objective cognitive testing, and patient self-report tests. Patients were examined using single voxel proton magnetic resonance spectroscopy in the medial frontal cortex, posterior cingulate gyrus, and left thalamus at baseline and after the completion of chemotherapy on a 1.5 Tesla scanner. At the posttreatment evaluation as compared to baseline, 7 of the 10 (70%) patients reported worsening memory on the MD Anderson symptom inventory (annualized change = 1.82 ± 2.88, P = .08), while the delayed recall raw score of the Rey Osterrieth complex figure test did not change from pre- to post-chemotherapy (mean annualized change = 5.00 ± 14.38, P = .30). The annualized change in the creatine concentration in the posterior cingulate gyrus was statistically significant. The annualized change in the MD Anderson symptom inventory was negatively correlated with the annualized change in the medial frontal N-acetylaspartate (Spearman correlation coefficient [rho] = -0.78, P = .01) and positively correlated with the annualized change in the posterior cingulate gyrus creatine (rho = 0.66, P = .04). Annualized changes in the Rey Osterrieth complex figure test were positively correlated with annualized changes in choline (rho = 0.83, P = .01) in the medial frontal cortex, choline (rho = 0.76, P = .04) in the left thalamus, and creatine (rho = 0.73, P = .02) in the medial frontal cortex. Our data suggest that chemotherapy may lead to the worsening of self-reported memory function, which is associated with alterations in brain metabolites., Competing Interests: The authors have no conflicts of interest to disclose., (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
4. Impact of ketamine versus propofol for anesthetic induction on cognitive dysfunction, delirium, and acute kidney injury following cardiac surgery in elderly, high-risk patients.
- Author
-
Wittwer ED, Cerhan JH, Schroeder DR, Schaff HV, and Mauermann WJ
- Subjects
- Aged, Humans, Prospective Studies, Propofol adverse effects, Ketamine adverse effects, Postoperative Cognitive Complications, Delirium epidemiology, Delirium etiology, Cognitive Dysfunction epidemiology, Cognitive Dysfunction etiology, Cardiac Surgical Procedures adverse effects, Acute Kidney Injury epidemiology, Acute Kidney Injury etiology, Anesthetics
- Abstract
Objective: Evaluate the effects of ketamine versus propofol when used for induction of anesthesia in elderly, high-risk cardiac surgical patients on postoperative complications including cognitive dysfunction, delirium, and acute kidney injury., Methods: Prospective, randomized study performed at a tertiary medical center. A total of 52 patients aged ≥70 and older presenting for complex cardiac surgery were randomized to receive either ketamine or propofol for induction of anesthesia. Patients underwent a battery of cognitive testing preoperatively and postoperatively and the incidence of delirium and acute kidney injury were measured. Norepinephrine (NEE) equivalents following induction were assessed for each group., Results: A total of 49 patients were included, 25 in the ketamine group and 24 in the propofol group with 3 patients excluded from the analysis. No difference was found between groups in either postoperative cognitive dysfunction or delirium incidence. Acute kidney injury occurred in 6 (24%) patients in the ketamine group in 12 (50%) patients in the propofol group, but the difference did not meet statistical significance (P = 0.08; Relative Risk = 2.1, 95% CI 0.9-4.7). NEE equivalents were lower in the ketamine group, 9.6 ± 22.2 versus 32.7 ± 46.0, P < 0.03., Conclusions: The use of ketamine versus propofol for induction of anesthesia did not impact the incidence of postoperative cognitive dysfunction or delirium. Twice as many patients in the propofol group developed acute kidney injury, although not reaching statistical significance and warranting further investigation. In elderly, high-risk patients, ketamine was associated with a significantly reduced need for vasopressor support following induction.
- Published
- 2023
- Full Text
- View/download PDF
5. Association of circulating markers with cognitive decline after radiation therapy for brain metastasis.
- Author
-
Huntoon K, Anderson SK, Ballman KV, Twohy E, Dooley K, Jiang W, An Y, Li J, von Roemeling C, Qie Y, Ross OA, Cerhan JH, Whitton AC, Greenspoon JN, Parney IF, Ashman JB, Bahary JP, Hadjipanayis C, Urbanic JJ, Farace E, Khuntia D, Laack NN, Brown PD, Roberge D, and Kim BYS
- Subjects
- Humans, Retrospective Studies, Amyloid beta-Peptides, Cranial Irradiation adverse effects, Cranial Irradiation methods, Brain Neoplasms secondary, Radiosurgery adverse effects, Radiosurgery methods, Cognitive Dysfunction etiology
- Abstract
Background: A recent phase III trial (NCT01372774) comparing use of stereotactic radiosurgery [SRS] versus whole-brain radiation therapy [WBRT] after surgical resection of a single brain metastasis revealed that declines in cognitive function were more common with WBRT than with SRS. A secondary endpoint in that trial, and the primary objective in this secondary analysis, was to identify baseline biomarkers associated with cognitive impairment after either form of radiotherapy for brain metastasis. Here we report our findings on APOE genotype and serum levels of associated proteins and their association with radiation-induced neurocognitive decline., Methods: In this retrospective analysis of prospectively collected samples from a completed randomized clinical trial, patients provided blood samples every 3 months that were tested by genotyping and enzyme-linked immunosorbent assay, and results were analyzed in association with cognitive impairment., Results: The APOE genotype was not associated with neurocognitive impairment at 3 months. However, low serum levels of ApoJ, ApoE, or ApoA protein (all P < .01) and higher amyloid beta (Aβ 1-42) levels (P = .048) at baseline indicated a greater likelihood of neurocognitive decline at 3 months after SRS, whereas lower ApoJ levels were associated with decline after WBRT (P = .014)., Conclusions: Patients with these pretreatment serum markers should be counseled about radiation-related neurocognitive decline., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
6. Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis: A Secondary Analysis of The N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group) Randomized Clinical Trial.
- Author
-
Palmer JD, Klamer BG, Ballman KV, Brown PD, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, and Roberge D
- Subjects
- Adult, Humans, Male, Female, Cranial Irradiation adverse effects, Cranial Irradiation methods, Quality of Life, Canada, Brain surgery, Radiosurgery adverse effects, Radiosurgery methods, Brain Neoplasms secondary
- Abstract
Importance: Long-term outcomes of radiotherapy are important in understanding the risks and benefits of therapies for patients with brain metastases., Objective: To determine how the use of postoperative whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) is associated with quality of life (QOL), cognitive function, and intracranial tumor control in long-term survivors with 1 to 4 brain metastases., Design, Setting, and Participants: This secondary analysis of a randomized phase 3 clinical trial included 48 institutions in the US and Canada. Adult patients with 1 resected brain metastases but limited to those with 1 to 4 brain metastasis were eligible. Unresected metastases were treated with SRS. Long-term survivors were defined as evaluable patients who lived longer than 1 year from randomization. Patients were recruited between July 2011 and December 2015, and data were first analyzed in February 2017. For the present study, intracranial tumor control, cognitive deterioration, QOL, and cognitive outcomes were measured in evaluable patients who were alive at 12 months from randomization and reanalyzed in June 2017., Interventions: Stereotactic radiosurgery or WBRT., Main Outcomes and Measures: Intracranial tumor control, toxic effects, cognitive deterioration, and QOL., Results: Fifty-four patients (27 SRS arm, 27 WBRT arm; female to male ratio, 65% vs 35%) were included for analysis with a median follow-up of 23.8 months. Cognitive deterioration was less frequent with SRS (37%-60%) compared with WBRT (75%-91%) at all time points. More patients declined by 2 or more standard deviations (SDs) in 1 or more cognitive tests for WBRT compared with SRS at 3, 6, and 9 months (70% vs 22%, 46% vs 19%, and 50% vs 20%, respectively). A 2 SD decline in at least 2 cognitive tests was associated with worse 12-month QOL in emotional well-being, functional well-being, general, additional concerns, and total scores. Overall QOL and functional independence favored SRS alone for categorical change at all time points. Total intracranial control for SRS alone vs WBRT at 12 months was 40.7% vs 81.5% (difference, -40.7; 95% CI, -68.1% to -13.4%), respectively. Data were first analyzed in February 2017., Conclusions and Relevance: The use of SRS alone compared with WBRT resulted in less cognitive deterioration among long-term survivors. The association of late cognitive deterioration with WBRT was clinically meaningful. A significant decline in cognition (2 SD) was associated with overall QOL. However, intracranial tumor control was improved with WBRT. This study provides detailed insight into cognitive function over time in this patient population., Trial Registration: ClinicalTrials.gov Identifier: NCT01372774; ALLIANCE/CCTG: N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group).
- Published
- 2022
- Full Text
- View/download PDF
7. CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
- Author
-
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, and Vogelbaum MA
- Subjects
- Adult, Humans, Isocitrate Dehydrogenase genetics, Progression-Free Survival, Temozolomide therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Oligodendroglioma drug therapy, Oligodendroglioma genetics
- Abstract
Background: We report the analysis involving patients treated on the initial CODEL design., Methods: Adults (>18) with newly diagnosed 1p/19q World Health Organization (WHO) grade III oligodendroglioma were randomized to radiotherapy (RT; 5940 centigray ) alone (arm A); RT with concomitant and adjuvant temozolomide (TMZ) (arm B); or TMZ alone (arm C). Primary endpoint was overall survival (OS), arm A versus B. Secondary comparisons were performed for OS and progression-free survival (PFS), comparing pooled RT arms versus TMZ-alone arm., Results: Thirty-six patients were randomized equally. At median follow-up of 7.5 years, 83.3% (10/12) TMZ-alone patients progressed, versus 37.5% (9/24) on the RT arms. PFS was significantly shorter in TMZ-alone patients compared with RT patients (hazard ratio [HR] = 3.12; 95% CI: 1.26, 7.69; P = 0.014). Death from disease progression occurred in 3/12 (25%) of TMZ-alone patients and 4/24 (16.7%) on the RT arms. OS did not statistically differ between arms (comparison underpowered). After adjustment for isocitrate dehydrogenase (IDH) status (mutated/wildtype) in a Cox regression model utilizing IDH and RT treatment status as covariables (arm C vs pooled arms A + B), PFS remained shorter for patients not receiving RT (HR = 3.33; 95% CI: 1.31, 8.45; P = 0.011), but not OS ((HR = 2.78; 95% CI: 0.58, 13.22, P = 0.20). Grade 3+ adverse events occurred in 25%, 42%, and 33% of patients (arms A, B, and C). There were no differences between arms in neurocognitive decline comparing baseline to 3 months., Conclusions: TMZ-alone patients experienced significantly shorter PFS than patients treated on the RT arms. The ongoing CODEL trial has been redesigned to compare RT + PCV versus RT + TMZ., (© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
8. Early Cutoff Criteria for Strong Performance on the Test of Memory Malingering.
- Author
-
Polsinelli AJ and Cerhan JH
- Subjects
- Adult, Humans, Memory and Learning Tests, Neuropsychological Tests, Reproducibility of Results, Malingering diagnosis, Memory Disorders diagnosis
- Abstract
Objective: The Test of Memory Malingering (TOMM) is widely used to assess performance validity. To improve efficiency, we investigated whether abbreviated administration (i.e., only the first 25 items of Trial 1 [T1]) is possible when effort is very strong (≥49/50 on T1 or T2)., Method: We collected TOMM scores of 501 consecutive adult patients ranging in cognitive status who underwent standard neuropsychological evaluation at Mayo Clinic, Rochester, MN., Results: Receiver Operating Characteristic (ROC) analysis showed excellent area under the curve (AUC) (0.94; CI95% [0.92, 0.97]) and a cutoff of 25/25 had 100% specificity for identifying strong performance. Of the 224 patients who obtained a perfect score on the first 25 items, 197 (88%) obtained ≥49 on T1 and the remaining patients (n = 27) obtained ≥49 on T2., Conclusion: A perfect score on the first 25 items of the TOMM predicted overall strong performance 100% of the time, supporting abbreviated administration in select cases in a general outpatient clinical setting., (© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
9. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.
- Author
-
Dubey D, Britton J, McKeon A, Gadoth A, Zekeridou A, Lopez Chiriboga SA, Devine M, Cerhan JH, Dunlay K, Sagen J, Ramberger M, Waters P, Irani SR, and Pittock SJ
- Subjects
- Aged, Autoantibodies blood, Double-Blind Method, Epilepsy immunology, Female, Humans, Immunoglobulin G blood, Immunoglobulin G immunology, Intracellular Signaling Peptides and Proteins blood, Male, Membrane Proteins blood, Middle Aged, Nerve Tissue Proteins blood, Treatment Outcome, Autoimmune Diseases drug therapy, Epilepsy drug therapy, Immunoglobulins, Intravenous therapeutic use, Intracellular Signaling Peptides and Proteins immunology, Membrane Proteins immunology, Nerve Tissue Proteins immunology
- Abstract
Objective: Drug-resistant seizures are common in patients with leucine-rich, glioma-inactivated 1 (LGI1)-IgG associated and contactin-associated protein-like 2 (CASPR2)-IgG associated encephalitis. We performed the first randomized double-blind placebo-controlled trial to evaluate efficacy of intravenous immunoglobulin (IVIG) in reducing seizure frequency., Methods: Our enrollment goal was 30 LGI1/CASPR2-IgG-seropositive adult patients with ≥2 seizures per week. Patients were randomized to receive IVIG (0.5g/kg day 1, 1g/kg day 2, 0.6g/kg weeks 3 and 5) or volume-matched intravenous normal saline. Following the blinded phase, the nonresponders in the placebo group received IVIG. The primary clinical outcome was 50% reduction in seizure frequency from baseline to 5 weeks., Results: After enrollment of 17 patients (LGI1-IgG, 14; CASPR2-IgG, 3) over 34 months, the study was terminated due to slow enrollment. Six of 8 patients in the IVIG group were responders, compared to 2 of 9 in the placebo group (p = 0.044, odds ratio = 10.5, 95% confidence interval = 1.1-98.9). For the LGI1-IgG seropositive subgroup, 6 of 8 patients in the IVIG group were responders, compared to zero of 6 in the placebo group. Two LGI1-IgG-seropositive patients receiving IVIG, but none receiving placebo, were seizure-free at the end of the blinded phase. Four of the 6 patients entering the open-label IVIG arm reported ≥50% reduction in seizure frequency. There were no correlations with LGI1/CASPR2-IgG1-4 subclasses., Interpretation: Superiority of IVIG to placebo reached statistical significance for the primary endpoint for all patients and the subset with LGI1-IgG. These results have to be interpreted with the caveat that the study did not reach its originally selected sample size. ANN NEUROL 2020;87:313-323., (© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.)
- Published
- 2020
- Full Text
- View/download PDF
10. Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3).
- Author
-
Trifiletti DM, Ballman KV, Brown PD, Anderson SK, Carrero XW, Cerhan JH, Whitton AC, Greenspoon J, Parney IF, Laack NN, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, and Roberge D
- Subjects
- Adult, Aged, Aged, 80 and over, Brain Neoplasms secondary, Brain Neoplasms surgery, Confidence Intervals, Cranial Irradiation adverse effects, Dose Fractionation, Radiation, Female, Humans, Kaplan-Meier Estimate, Lung Neoplasms pathology, Male, Middle Aged, Proportional Hazards Models, Prospective Studies, Radiosurgery adverse effects, Radiotherapy, Adjuvant adverse effects, Radiotherapy, Adjuvant standards, Brain Neoplasms radiotherapy, Cognition Disorders prevention & control, Cranial Irradiation standards, Quality Improvement, Radiosurgery standards
- Abstract
Purpose: Whole brain radiation therapy (WBRT) remains a commonly used cancer treatment, although controversy exists regarding the optimal dose/fractionation to optimize intracranial tumor control and minimize resultant cognitive deficits., Methods and Materials: NCCTG N107C [Alliance]/CEC.3 randomized 194 patients with brain metastases to either stereotactic radiosurgery alone or WBRT after surgical resection. Among the 92 patients receiving WBRT, sites predetermined the dose/fractionation that would be used for all patients treated at that site (either 30 Gy in 10 fractions or 37.5 Gy in 15 fractions). Analyses were performed using Kaplan-Meier estimates, log rank tests, and Fisher's exact tests., Results: Among 92 patients treated with surgical resection and adjuvant WBRT, 49 were treated with 30 Gy in 10 fractions (53%), and 43 were treated with 37.5 Gy in 15 fractions (47%). Baseline characteristics, including cognitive testing, were well balanced between groups with the exception of primary tumor type (lung cancer histology was more frequent with protracted WBRT: 72% vs 45%, P = .01), and 93% of patients completed the full course of WBRT. A more protracted WBRT dose regimen (37.5 Gy in 15 fractions) did not significantly affect time to cognitive failure (hazard ratio [HR], 0.9; 95% confidence interval [CI], 0.6-1.39; P = .66), surgical bed control (HR, 0.52 [95% CI, 0.22-1.25], P = .14), intracranial tumor control (HR, 0.56 [95% CI, 0.28-1.12], P = .09), or overall survival (HR, 0.72 [95% CI, 0.45-1.16], P = .18). Although there was no reported radionecrosis, there is a statistically significant increase in the risk of at least 1 grade ≥3 adverse event with 37.5 Gy in 15 fractions versus 30 Gy in 10 fractions (54% vs 31%, respectively, P = .03)., Conclusions: This post hoc analysis does not demonstrate that protracted WBRT courses reduce the risk of cognitive deficit, improve tumor control in the hypoxic surgical cavity, or otherwise improve the therapeutic ratio. Adverse events were significantly higher with the lengthened course of WBRT. For patients with brain metastases where WBRT is recommended, shorter course hypofractionated regimens remain the current standard of care., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
11. Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology.
- Author
-
Cerhan JH, Anderson SK, Butts AM, Porter AB, Jaeckle K, Galanis E, and Brown PD
- Abstract
Background: Cognitive function is an important outcome in brain-tumor clinical trials. Cognitive examiners are often needed across multiple sites, many of whom have no prior testing experience. To ensure quality, we looked at examiner errors in administering a commonly used cognitive test battery, determined whether the errors were correctable upon central review, and considered whether the same errors would be detected using onsite electronic data entry., Methods: We looked at 500 cognitive exams administered for brain-tumor trials led by the Alliance for Clinical Trials in Oncology (Alliance). Of 2277 tests examined, 32 noncorrectable errors were detected with routine central review (1.4% of tests administered), and thus removed from the database of the respective trial. The invalidation rate for each test was 0.8% for each part of the Hopkins Verbal Learning Test-Revised, 0.8% for Controlled Oral Word Association, 1.8% for Trail Making Test-A and 2.6% for Trail Making Test-B. It was estimated that, with onsite data entry and no central review, 4.9% of the tests entered would have uncorrected errors and 1.3% of entered tests would be frankly invalid but not removed., Conclusions: Cognitive test results are useful and robust outcome measures for brain-tumor clinical trials. Error rates are extremely low, and almost all are correctable with central review of scoring, which is easy to accomplish. We caution that many errors could be missed if onsite electronic entry is utilized instead of central review, and it would be important to mitigate the risk of invalid scores being entered., Clinicaltrialsgov Identifiers: NCT01781468 (Alliance A221101), NCT01372774 (NCCTG N107C), NCT00731731 (NCCTG N0874), and NCT00887146 (NCCTG N0577).
- Published
- 2019
- Full Text
- View/download PDF
12. Factors Associated With Meningioma Detected in a Population-Based Sample.
- Author
-
Cerhan JH, Butts AM, Syrjanen JA, Aakre JA, Brown PD, Petersen RC, Jack CR Jr, and Roberts RO
- Subjects
- Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Body Mass Index, Coronary Artery Disease complications, Female, Hormone Replacement Therapy adverse effects, Humans, Incidence, Male, Meningeal Neoplasms epidemiology, Meningeal Neoplasms etiology, Meningioma epidemiology, Meningioma etiology, Minnesota epidemiology, Odds Ratio, Retrospective Studies, Risk Factors, Brain diagnostic imaging, Incidental Findings, Magnetic Resonance Imaging methods, Meningeal Neoplasms diagnosis, Meningioma diagnosis, Population Surveillance, Risk Assessment methods
- Abstract
Objective: To determine the frequency of incidental meningioma and identify associated factors in a population-based sample of participants who systematically underwent brain imaging., Patients and Methods: We searched the Mayo Clinic Study of Aging, a population-based sample of Olmsted County, Minnesota, residents who underwent longitudinal magnetic resonance imaging of the brain. Using a text search of radiologists' notes for 2402 individuals (median age, 75.0 years) who underwent imaging between August 10, 2005, and July 31, 2014, we identified 52 patients (2.2%) who had at least one meningioma. We estimated the association of selected risk factors with the presence of meningioma using odds ratios and 95% CIs from logistic regression models adjusted for age and sex. Based on these results, we moved the most significant variables forward to a multivariable model., Results: Controlling for age and sex, significant associations with the presence of meningioma included higher body mass index (odds ratio [OR], 1.06; 95% CI, 1.01-1.12; P=.03), nonsteroidal anti-inflammatory drugs (OR, 2.11; 95% CI, 1.13-3.95; P=.02), aspirin (OR, 1.90; 95% CI, 1.05-3.46; P=.04), and blood pressure-lowering medication (OR, 2.06; 95% CI, 1.06-3.99; P=.03). Lower risk was associated with male sex (OR, 0.51; 95% CI, 0.29-0.90; P=.02), coronary artery disease (OR, 0.46; 95% CI, 0.22-0.97; P=.04), and higher self-reported anxiety (OR, 0.88; 95% CI, 0.78-0.98; P=.02). Simultaneous adjustment for all of these factors except aspirin in a multivariable model did not attenuate these associations (concordance, 0.71)., Conclusion: In a population-based sample of 2402 participants, 52 (2.2%) had an incidental meningioma. They were more likely to be female and have higher body mass index. Meningioma was also associated with certain medications (nonsteroidal anti-inflammatory drugs and blood pressure-lowering medications) and inversely with anxiety and coronary artery disease., (Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
13. Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma.
- Author
-
Cerhan JH, Caine C, Anderson SK, Johnson DR, Lachance DH, Yan E, and Brown PD
- Abstract
Background: Cognitive function is an important outcome measure in many brain tumor clinical trials, and investigators are interested in employing the most efficient methods of cognitive assessment for this purpose. Computerized testing can be appealing because of the perceived ease of use and electronic data generated. Traditional tests may have the advantage of accumulated validity evidence and comparability across historic trials., Methods: We evaluated feasibility of a Cogstate battery in 39 patients with high-grade glioma, and compared it with a commonly used paper-and-pencil battery., Results: Both batteries were well tolerated and rated equally likeable. Correlations between the batteries were low to low-moderate. More patients showed impairment at baseline and decline across trials on traditional tests., Conclusions: Both batteries were well tolerated, but the most complicated tasks (from both batteries) could not be completed by all subjects. Preliminary validity evidence for the Cogstate tasks was mixed, but a larger sample is needed.
- Published
- 2019
- Full Text
- View/download PDF
14. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.
- Author
-
Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, Cerhan JH, Anderson SK, Carrero XW, Garces YI, Barker FG 2nd, Deming R, Dixon JG, Burri SH, Chung C, Ménard C, Stieber VW, Pollock BE, Galanis E, Buckner JC, and Asher AL
- Subjects
- Brain Neoplasms radiotherapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Combined Modality Therapy methods, Cranial Irradiation methods, Humans, Prognosis, Radiosurgery methods, Radiotherapy, Adjuvant methods, Radiotherapy, Adjuvant mortality, Brain Neoplasms mortality, Brain Neoplasms secondary, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung secondary, Cranial Irradiation mortality, Lung Neoplasms pathology, Radiosurgery mortality
- Abstract
Purpose: To determine whether whole-brain radiation therapy (WBRT) is associated with improved overall survival among non-small cell lung cancer (NSCLC) patients with favorable prognoses at diagnosis., Methods and Materials: In the N0574 trial, patients with 1 to 3 brain metastases were randomized to receive stereotactic radiosurgery (SRS) or SRS plus WBRT (SRS + WBRT), with a primary endpoint of cognitive deterioration. We calculated diagnosis-specific graded prognostic assessment (DS-GPA) scores for NSCLC patients and evaluated overall survival according to receipt of WBRT and DS-GPA score using 2 separate cut-points (≥2.0 vs <2.0 and ≥2.5 vs <2.5)., Results: A total of 126 NSCLC patients were included for analysis, with median follow-up of 14.2 months. Data for DS-GPA calculation were available for 86.3% of all enrolled NSCLC patients. Overall, 50.0% of patients had DS-GPA score ≥2.0, and 23.0% of patients had DS-GPA scores ≥2.5. The SRS and SRS + WBRT groups were well balanced with regard to prognostic factors. The median survival according to receipt of WBRT was 11.3 months (+WBRT) and 17.9 months (-WBRT) for patients with DS-GPA ≥2.0 (favorable prognoses, P=.63; hazard ratio 0.86; 95% confidence interval 0.47-1.59). Median survival was 3.7 months (+WBRT) and 6.6 months (-WBRT) for patients with DS-GPA <2.0 patients (unfavorable prognoses, P=.85; hazard ratio 0.95; 95% confidence interval 0.56-1.62). Outcomes according to the receipt of WBRT and DS-GPA remained similar utilizing DS-GPA ≥2.5 as a cutoff for favorable prognoses. There was no interaction between the continuum of the DS-GPA groups and WBRT on overall survival (P=.53)., Conclusions: We observed no significant differences in survival according to receipt of WBRT in favorable-prognosis NSCLC patients. This study further supports the approach of SRS alone in the majority of patients with limited brain metastases., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
15. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
- Author
-
Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, Greenspoon J, Parney IF, Laack NNI, Ashman JB, Bahary JP, Hadjipanayis CG, Urbanic JJ, Barker FG 2nd, Farace E, Khuntia D, Giannini C, Buckner JC, Galanis E, and Roberge D
- Subjects
- Activities of Daily Living, Adolescent, Adult, Brain Neoplasms secondary, Disease Progression, Disease-Free Survival, Dose Fractionation, Radiation, Female, Follow-Up Studies, Humans, Intention to Treat Analysis, Magnetic Resonance Imaging, Male, Metastasectomy, Middle Aged, Quality of Life, Radiotherapy, Adjuvant, Survival Rate, Young Adult, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Cognition Disorders etiology, Neoplasm Recurrence, Local diagnostic imaging, Radiosurgery adverse effects
- Abstract
Background: Whole brain radiotherapy (WBRT) is the standard of care to improve intracranial control following resection of brain metastasis. However, stereotactic radiosurgery (SRS) to the surgical cavity is widely used in an attempt to reduce cognitive toxicity, despite the absence of high-level comparative data substantiating efficacy in the postoperative setting. We aimed to establish the effect of SRS on survival and cognitive outcomes compared with WBRT in patients with resected brain metastasis., Methods: In this randomised, controlled, phase 3 trial, adult patients (aged 18 years or older) from 48 institutions in the USA and Canada with one resected brain metastasis and a resection cavity less than 5·0 cm in maximal extent were randomly assigned (1:1) to either postoperative SRS (12-20 Gy single fraction with dose determined by surgical cavity volume) or WBRT (30 Gy in ten daily fractions or 37·5 Gy in 15 daily fractions of 2·5 Gy; fractionation schedule predetermined for all patients at treating centre). We randomised patients using a dynamic allocation strategy with stratification factors of age, duration of extracranial disease control, number of brain metastases, histology, maximal resection cavity diameter, and treatment centre. Patients and investigators were not masked to treatment allocation. The co-primary endpoints were cognitive-deterioration-free survival and overall survival, and analyses were done by intention to treat. We report the final analysis. This trial is registered with ClinicalTrials.gov, number NCT01372774., Findings: Between Nov 10, 2011, and Nov 16, 2015, 194 patients were enrolled and randomly assigned to SRS (98 patients) or WBRT (96 patients). Median follow-up was 11·1 months (IQR 5·1-18·0). Cognitive-deterioration-free survival was longer in patients assigned to SRS (median 3·7 months [95% CI 3·45-5·06], 93 events) than in patients assigned to WBRT (median 3·0 months [2·86-3·25], 93 events; hazard ratio [HR] 0·47 [95% CI 0·35-0·63]; p<0·0001), and cognitive deterioration at 6 months was less frequent in patients who received SRS than those who received WBRT (28 [52%] of 54 evaluable patients assigned to SRS vs 41 [85%] of 48 evaluable patients assigned to WBRT; difference -33·6% [95% CI -45·3 to -21·8], p<0·00031). Median overall survival was 12·2 months (95% CI 9·7-16·0, 69 deaths) for SRS and 11·6 months (9·9-18·0, 67 deaths) for WBRT (HR 1·07 [95% CI 0·76-1·50]; p=0·70). The most common grade 3 or 4 adverse events reported with a relative frequency greater than 4% were hearing impairment (three [3%] of 93 patients in the SRS group vs eight [9%] of 92 patients in the WBRT group) and cognitive disturbance (three [3%] vs five [5%]). There were no treatment-related deaths., Interpretation: Decline in cognitive function was more frequent with WBRT than with SRS and there was no difference in overall survival between the treatment groups. After resection of a brain metastasis, SRS radiosurgery should be considered one of the standards of care as a less toxic alternative to WBRT for this patient population., Funding: National Cancer Institute., (Copyright © 2017 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
16. Neurocognition in individuals with incidentally-identified meningioma.
- Author
-
Butts AM, Weigand S, Brown PD, Petersen RC, Jack CR Jr, Machulda MM, and Cerhan JH
- Subjects
- Aged, Aged, 80 and over, Analysis of Variance, Apolipoproteins E genetics, Attention physiology, Cognition Disorders epidemiology, Community Health Planning, Female, Humans, Language, Longitudinal Studies, Magnetic Resonance Imaging, Male, Memory physiology, Meningeal Neoplasms diagnostic imaging, Meningeal Neoplasms epidemiology, Meningeal Neoplasms genetics, Meningioma diagnostic imaging, Meningioma epidemiology, Meningioma genetics, Middle Aged, Neuropsychological Tests, Visual Perception genetics, Cognition Disorders etiology, Meningeal Neoplasms complications, Meningioma complications
- Abstract
Meningiomas are primary intracranial tumors that are often asymptomatic. To our knowledge, no study has attempted to describe neurocognitive function in patients with incidentally-discovered meningioma. We utilized the Mayo Clinic Study of Aging (MCSA), which is a population-based sample of Olmsted County, Minnesota residents that includes neuropsychological testing and brain MRI approximately every 15 months. Using a text search of radiologists' notes of 2402 MCSA individuals (mean age 77 years, scanned between 2004 and 2014) we identified 48 eligible subjects (2%) who had at least one meningioma. Most meningiomas were small (90% <3 cm). We matched each of the 48 subjects to 5 non-demented MCSA controls (n = 240) on age, sex, and education. Cognitive domains assessed included memory, attention-executive function, language, and visuospatial. More women (67%) had a meningioma than men (33%). Groups did not differ on prevalence of Mild Cognitive Impairment (Meningioma = 19%, Controls = 13%). Across cognitive domains, we observed similar performance for the two groups (p's ≥ 0.21). Subtle differences emerged in memory and language domains (p = 0.05 and p = 0.11) when we divided the Meningioma group by tumor location, wherein the small group with an infratentorial tumor performed more poorly than controls globally as well as on select memory and language measures. Our findings suggest that small meningiomas are generally cognitively benign, but that may change as the tumor evolves, and might be impacted by other factors such as meningioma location.
- Published
- 2017
- Full Text
- View/download PDF
17. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.
- Author
-
Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG 2nd, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, and Asher AL
- Subjects
- Adult, Aged, Brain Neoplasms mortality, Brain Neoplasms secondary, Combined Modality Therapy methods, Dose Fractionation, Radiation, Female, Humans, Male, Middle Aged, Quality of Life, Radiosurgery, Survival Analysis, Survivors, Time Factors, Brain Neoplasms radiotherapy, Brain Neoplasms surgery, Cognition radiation effects, Cognition Disorders etiology, Cranial Irradiation
- Abstract
Importance: Whole brain radiotherapy (WBRT) significantly improves tumor control in the brain after stereotactic radiosurgery (SRS), yet because of its association with cognitive decline, its role in the treatment of patients with brain metastases remains controversial., Objective: To determine whether there is less cognitive deterioration at 3 months after SRS alone vs SRS plus WBRT., Design, Setting, and Participants: At 34 institutions in North America, patients with 1 to 3 brain metastases were randomized to receive SRS or SRS plus WBRT between February 2002 and December 2013., Interventions: The WBRT dose schedule was 30 Gy in 12 fractions; the SRS dose was 18 to 22 Gy in the SRS plus WBRT group and 20 to 24 Gy for SRS alone., Main Outcomes and Measures: The primary end point was cognitive deterioration (decline >1 SD from baseline on at least 1 cognitive test at 3 months) in participants who completed the baseline and 3-month assessments. Secondary end points included time to intracranial failure, quality of life, functional independence, long-term cognitive status, and overall survival., Results: There were 213 randomized participants (SRS alone, n = 111; SRS plus WBRT, n = 102) with a mean age of 60.6 years (SD, 10.5 years); 103 (48%) were women. There was less cognitive deterioration at 3 months after SRS alone (40/63 patients [63.5%]) than when combined with WBRT (44/48 patients [91.7%]; difference, -28.2%; 90% CI, -41.9% to -14.4%; P < .001). Quality of life was higher at 3 months with SRS alone, including overall quality of life (mean change from baseline, -0.1 vs -12.0 points; mean difference, 11.9; 95% CI, 4.8-19.0 points; P = .001). Time to intracranial failure was significantly shorter for SRS alone compared with SRS plus WBRT (hazard ratio, 3.6; 95% CI, 2.2-5.9; P < .001). There was no significant difference in functional independence at 3 months between the treatment groups (mean change from baseline, -1.5 points for SRS alone vs -4.2 points for SRS plus WBRT; mean difference, 2.7 points; 95% CI, -2.0 to 7.4 points; P = .26). Median overall survival was 10.4 months for SRS alone and 7.4 months for SRS plus WBRT (hazard ratio, 1.02; 95% CI, 0.75-1.38; P = .92). For long-term survivors, the incidence of cognitive deterioration was less after SRS alone at 3 months (5/11 [45.5%] vs 16/17 [94.1%]; difference, -48.7%; 95% CI, -87.6% to -9.7%; P = .007) and at 12 months (6/10 [60%] vs 17/18 [94.4%]; difference, -34.4%; 95% CI, -74.4% to 5.5%; P = .04)., Conclusions and Relevance: Among patients with 1 to 3 brain metastases, the use of SRS alone, compared with SRS combined with WBRT, resulted in less cognitive deterioration at 3 months. In the absence of a difference in overall survival, these findings suggest that for patients with 1 to 3 brain metastases amenable to radiosurgery, SRS alone may be a preferred strategy., Trial Registration: clinicaltrials.gov Identifier: NCT00377156.
- Published
- 2016
- Full Text
- View/download PDF
18. Exploring primary brain tumor patient and caregiver needs and preferences in brief educational and support opportunities.
- Author
-
Lageman SK, Brown PD, Anderson SK, Lachance DH, Yan E, Laack NN, and Cerhan JH
- Subjects
- Adaptation, Psychological, Adult, Aged, Behavior Therapy methods, Data Collection, Female, Health Services Needs and Demand, Humans, Middle Aged, Motivation, Psychotherapy, Group methods, Social Support, Brain Neoplasms psychology, Brain Neoplasms therapy, Caregivers education, Caregivers psychology, Patient Education as Topic methods, Patient Preference, Psychotherapy, Brief methods
- Abstract
Purpose: A primary brain tumor patient and caregiver survey was completed to investigate interest in brief support opportunities, focused on education, memory training, and healthy coping, during a routine clinical visit and at 3-month follow-up., Methods: Patients with primary brain tumors receiving care in the Radiation Oncology Department at Mayo Clinic Rochester and their caregivers were recruited to complete the survey between June 2008 and September 2009., Results: Both patients and their caregivers expressed greatest interest in education about brain tumors and cognitive effects of treatment. Interest in support opportunities targeting education, memory training, or healthy coping was low to modest. Bimodal distributions were found for almost all the support opportunities, revealing subgroups of patients and caregivers with high interest in such sessions. Overall, ratings of interest did not differ over time., Conclusions: Patients with primary brain tumors and their caregivers expressed most interest in education about their disease and potential cognitive effects of treatment. It appears that subgroups of patients and caregivers have very high interest in brief support opportunities. Identifying these subgroups of patients and families will allow targeted interventions focused on their needs and make the best use of limited resources.
- Published
- 2015
- Full Text
- View/download PDF
19. A novel VCP mutation underlies scapuloperoneal muscular dystrophy and dropped head syndrome featuring lobulated fibers.
- Author
-
Liewluck T, Milone M, Mauermann ML, Castro-Couch M, Cerhan JH, and Murthy NS
- Subjects
- Humans, Kyphosis complications, Male, Middle Aged, Muscular Dystrophy, Emery-Dreifuss complications, Valosin Containing Protein, Adenosine Triphosphatases genetics, Cell Cycle Proteins genetics, Kyphosis genetics, Muscular Dystrophy, Emery-Dreifuss genetics, Mutation genetics
- Abstract
Introduction: Valosin-containing protein (VCP) is a ubiquitously expressed, multifunctional AAA-ATPase protein. Its dominant mutations cause hereditary inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia (IBMPFD) or amyotrophic lateral sclerosis. The pattern of muscle weakness in IBMPFD patients is variable and includes limb-girdle, scapuloperoneal, distal, or axial distributions., Case Report: We report a 63-year-old man with progressive scapuloperoneal weakness, head drop, and hyperCKemia since age 40 years. Electromyography showed myopathic changes and rare myotonic discharges. Muscle biopsy revealed numerous lobulated fibers, few fibers with glycogen accumulation, and rare fibers with polyglucosan bodies. Rimmed vacuoles and congophilic inclusions, often seen in IBMPFD, were absent. VCP sequencing identified a novel heterozygous c. 1160G>A mutation resulting in p.Asn387Ser substitution., Conclusions: Our patient broadens the pathological spectrum of VCP-myopathy and emphasizes the importance of VCP analysis in patients with scapuloperoneal muscular dystrophy despite the absence of Paget disease, dementia, rimmed vacuoles, or intracellular amyloid deposition., (Copyright © 2014 Wiley Periodicals, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
20. Treatment of persistent/medically refractory covert hepatic encephalopathy with the molecular adsorbent recirculating system.
- Author
-
Leise MD, Leung N, El-Zoghby Z, Gonzalez Gonzalez HC, Cerhan JH, and Nyberg SL
- Subjects
- Abdominal Abscess etiology, Aged, Albumins chemistry, Catheterization, Humans, Hypertension, Portal etiology, Male, Peritonitis microbiology, Portal Vein pathology, Postoperative Period, Reoperation, Treatment Outcome, Venous Thrombosis etiology, Carcinoma, Hepatocellular therapy, End Stage Liver Disease therapy, Hepatic Encephalopathy therapy, Liver Cirrhosis therapy, Liver Neoplasms therapy, Renal Dialysis methods, Sorption Detoxification methods
- Published
- 2014
- Full Text
- View/download PDF
21. Correction for a potentially biased item on the Mattis dementia rating scale.
- Author
-
Dean PM and Cerhan JH
- Subjects
- Aged, Aged, 80 and over, Cultural Competency, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Psychometrics instrumentation, Dementia diagnosis
- Abstract
The Mattis Dementia Rating Scale (MDRS) is a multidimensional cognitive measure popular with clinicians for its brevity, diagnostic validity, and utility in monitoring impairment severity. In spite of the test's significant value, one task can cause discomfort because the patient is asked to name items the examiner is wearing. This task also creates possible cultural bias and standardization issues. We studied 102 MDRS profiles that included this item. Adjusted scores were calculated by giving all patients full credit for the apparel-naming item. The average adjustment was just one point, and the resulting dementia-severity ratings remained unchanged in 97% of the patients. These results show that administration of the item can be defensibly skipped if there is concern about its appropriateness with an individual patient. The adjusted scores provide a viable and fair alternative that preserves the psychometric properties of this useful instrument.
- Published
- 2013
- Full Text
- View/download PDF
22. Looking into learning: visuospatial and psychomotor predictors of ultrasound-guided procedural performance.
- Author
-
Smith HM, Kopp SL, Johnson RL, Long TR, Cerhan JH, and Hebl JR
- Subjects
- Adult, Female, Humans, Learning, Male, Ultrasonics, Anesthesia, Conduction methods, Anesthesiology education, Internship and Residency, Psychomotor Performance
- Abstract
Background and Objectives: Despite widespread use of ultrasound in regional anesthesia, little understanding of the psychomotor and visuospatial skills required to achieve and maintain procedural proficiency exists. Despite its procedural nature, anesthesiology lags behind other fields in assessing technical aptitude among practitioners and trainees. The goals of this study were to measure relevant visuospatial and psychomotor aptitudes of anesthesia residents-in-training and to evaluate the relationship between these skill sets and the performance of ultrasound-guided regional anesthesia., Methods: Forty residents from the Mayo Clinic Department of Anesthesiology were enrolled, and 39 (PGY-1 through PGY-4) voluntarily completed a demographic survey, 4 psychomotor and 4 visuospatial aptitude assessments, and an ultrasound-based performance assessment., Results: The Block Design Test, a subtest of the Wechsler Adult Intelligent Scale - III, correlated with ultrasound guided skill performance (correlation coefficient, 0.47; P < 0.002). By contrast, psychomotor aptitude assessments did not correlate with ultrasound task performance. Psychomotor skill performance was significantly reduced by indirect hand-eye coordination visual feedback (projected image) compared with direct hand-eye coordination (P < 0.001). A learning effect was observed between the first and second ultrasound skill task attempts and was independent of hand dominance., Discussion: This study reveals that visuospatial aptitude is a better predictor of ultrasound-based procedural performance than psychomotor ability. The type of real-time visual feedback (indirect versus direct) used for hand-eye coordination significantly impacts procedural performance and has implications for anesthesia and other procedural specialties. The learning effect noted during initial ultrasound skill trials suggests visuospatial assimilation and underscores the importance of early ultrasound instruction.
- Published
- 2012
- Full Text
- View/download PDF
23. Selective serotonin reuptake inhibitors, glioblastoma multiforme, and impact on toxicities and overall survival: the mayo clinic experience.
- Author
-
Caudill JS, Brown PD, Cerhan JH, and Rummans TA
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Brain Neoplasms complications, Brain Neoplasms mortality, Child, Child, Preschool, Cohort Studies, Depressive Disorder etiology, Female, Follow-Up Studies, Glioblastoma complications, Glioblastoma mortality, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Treatment Outcome, Young Adult, Antidepressive Agents therapeutic use, Brain Neoplasms therapy, Depressive Disorder drug therapy, Depressive Disorder mortality, Glioblastoma therapy, Selective Serotonin Reuptake Inhibitors therapeutic use
- Abstract
Purpose: The diagnoses of glioblastoma multiforme (GBM) and depression are often found to coexist. The impact of selective serotonin reuptake inhibitors (SSRI) on treatment-related toxicity and outcome in patients with GBM is unclear., Methods and Materials: We retrospectively reviewed 160 patients with GBM who received treatment at our institution between 1999 and 2008. Those taking an SSRI during treatment for GBM were identified and toxicities were assessed., Results: Median survival for the entire cohort was 1.05 years. A total of 35 patients (21.8%) took an SSRI during initial treatment for GBM. There was no statistical difference in the rate of ≥grade 3 toxicity in patients taking an SSRI when compared with those who were not (11.4% vs. 13.6%, respectively; P = 1.00). Two-year survival in the cohort of patients taking an SSRI was 32% versus 17% in those who were not (P = 0.18). After making adjustment for age, recursive partitioning analysis class, and extent of surgery, absence of an SSRI during treatment was associated with a hazard risk of 1.5 (95% confidence interval = 1.00-2.42; P = 0.05)., Conclusions: This retrospective review suggests that concomitant use of an SSRI during treatment does not adversely affect survival. There was no increased toxicity with the use of SSRI concurrent with treatment of newly-diagnosed GBM.
- Published
- 2011
- Full Text
- View/download PDF
24. Sporadic corticobasal syndrome with progranulin mutation presenting as progressive apraxic agraphia.
- Author
-
Passov V, Gavrilova RH, Strand E, Cerhan JH, and Josephs KA
- Subjects
- Agraphia diagnostic imaging, Agraphia psychology, Basal Ganglia Diseases diagnostic imaging, Basal Ganglia Diseases psychology, Brain pathology, Female, Fluorodeoxyglucose F18, Functional Laterality physiology, Handwriting, Humans, Magnetic Resonance Imaging, Middle Aged, Neuropsychological Tests, Positron-Emission Tomography, Progranulins, Radiopharmaceuticals, Agraphia genetics, Basal Ganglia Diseases genetics, Intercellular Signaling Peptides and Proteins genetics, Mutation physiology
- Abstract
Objective: To examine the relationship between progranulin gene mutation and apraxic agraphia., Design: Case report., Setting: Tertiary care medical center., Patient: A 49-year-old right-handed woman who presented with apraxic agraphia that progressed into the corticobasal syndrome., Results: This woman had no family history of neurodegenerative disease. Magnetic resonance imaging and fluorodeoxyglucose positron emission tomographic scans of her head revealed significant asymmetric frontoparietal abnormalities, in keeping with the clinical diagnosis of corticobasal syndrome. Progranulin gene sequencing identified a 4-base pair deletion., Conclusions: Patients presenting with early apraxic agraphia, a progressive disease course, and asymmetric frontoparietal abnormalities on brain scans should be considered for progranulin gene testing despite negative family history.
- Published
- 2011
- Full Text
- View/download PDF
25. Comparing neuropsychological tasks to optimize brief cognitive batteries for brain tumor clinical trials.
- Author
-
Lageman SK, Cerhan JH, Locke DE, Anderson SK, Wu W, and Brown PD
- Subjects
- Adult, Aged, Antineoplastic Agents, Alkylating pharmacology, Antineoplastic Agents, Alkylating therapeutic use, Attention drug effects, Attention physiology, Brain Neoplasms drug therapy, Dacarbazine analogs & derivatives, Dacarbazine pharmacology, Dacarbazine therapeutic use, Female, Humans, Language, Male, Memory drug effects, Memory physiology, Middle Aged, Neuropsychological Tests, Retrospective Studies, Space Perception drug effects, Space Perception physiology, Temozolomide, Brain Neoplasms complications, Cognition Disorders diagnosis, Cognition Disorders etiology
- Abstract
Neuropsychological tests are increasingly being used as outcome measures in clinical trials of brain tumor therapies. This study informs development of brief neurocognitive batteries for clinical trials by identifying cognitive tasks that detect effects on a group level in a mixed brain tumor population. This is a retrospective study of brain tumor patients who completed a standardized battery sampling multiple cognitive domains using twelve subtests with widely-used task formats (the Repeatable Battery for the Assessment of Neuropsychological Status). Sixty-eight patients with brain tumors were studied (60% high-grade glioma). Forty patients (58.8%) were impaired (>2 standard deviations below published means) on at least one subtest. A combination of four subtests (Figure Copy, Coding, List Recognition, and Story Recall) captured 90% of the impaired subgroup. These results suggest visuoconstruction, processing speed, and verbal memory measures may be the most important domains to assess when evaluating cognitive change in brain tumor clinical trials.
- Published
- 2010
- Full Text
- View/download PDF
26. Same, better, or worse? Neurocognitive effects of radiotherapy for low-grade gliomas remain unknown.
- Author
-
Brown PD and Cerhan JH
- Subjects
- Antineoplastic Protocols standards, Attention physiology, Attention radiation effects, Brain pathology, Brain physiopathology, Brain Neoplasms pathology, Brain Neoplasms physiopathology, Clinical Trials as Topic standards, Clinical Trials as Topic statistics & numerical data, Cognition Disorders physiopathology, Disease Progression, Glioma pathology, Glioma physiopathology, Humans, Neurosurgical Procedures adverse effects, Neurosurgical Procedures statistics & numerical data, Radiation Dosage, Radiotherapy methods, Selection Bias, Brain radiation effects, Brain Neoplasms radiotherapy, Cognition Disorders etiology, Glioma radiotherapy, Radiotherapy adverse effects
- Published
- 2009
- Full Text
- View/download PDF
27. Cognitive rehabilitation and problem-solving to improve quality of life of patients with primary brain tumors: a pilot study.
- Author
-
Locke DE, Cerhan JH, Wu W, Malec JF, Clark MM, Rummans TA, and Brown PD
- Subjects
- Adult, Affect, Aged, Fatigue etiology, Female, Humans, Male, Middle Aged, Patient Satisfaction, Pilot Projects, Brain Neoplasms psychology, Cognition Disorders rehabilitation, Problem Solving, Quality of Life
- Abstract
Caregivers of patients with brain tumors frequently identify cognitive impairment in their loved ones as their greatest burden, but only one published study has examined a cognitive-rehabilitation intervention for adults with brain tumors. Emotional distress and poor quality of life (QOL) also have been identified as important issues, yet they have been excluded from most intervention studies that target coping and mood. The primary aim of this pilot study was to determine the feasibility and tolerability of a combined cognitive-rehabilitation and problem-solving-therapy intervention for patients with brain tumors and their caregivers. In all, 19 patient/caregiver pairs were enrolled and randomized, and 13 pairs completed the 2-week trial. After receiving the intervention, 88% of patients used the study-specific strategies, and 88% indicated that they would recommend the intervention to other patients diagnosed with a brain tumor. The study intervention was described as "very helpful" or "somewhat helpful" by 88% of study participants. Caregivers were similarly enthusiastic about the intervention. The results showed that patients with brain tumors who have cognitive impairment can participate meaningfully in a structured intervention, and they supported further research into the potential effectiveness of formal rehabilitation targeting cognitive and QOL symptoms for patients with brain tumors and their caregivers.
- Published
- 2008
28. Alzheimer's disease patients' cognitive status and course years prior to symptom recognition.
- Author
-
Cerhan JH, Ivnik RJ, Smith GE, Machulda MM, Boeve BF, Knopman DS, Petersen RC, and Tangalos EG
- Subjects
- Aged, Aged, 80 and over, Analysis of Variance, Cohort Studies, Disease Progression, Female, Humans, Male, Neuropsychological Tests, Reproducibility of Results, Time Factors, Alzheimer Disease diagnosis, Alzheimer Disease physiopathology, Cognition physiology, Recognition, Psychology physiology
- Abstract
This is a prospective examination of the cognitive performance and cognitive course of persons in an asymptomatic "preclinical" phase who eventually developed Alzheimer's disease (AD). We compared performances on the Mayo Cognitive Factor Scales (MCFS) of 20 persons in a neurologically normal cohort who subsequently developed AD to the performances of 60 persons who remained free of dementia symptoms. For the AD patients, exams occurred prior to the appearance of dementia symptoms (an average of 4.2 and 1.5 years prior to symptom onset). Results reveal strong group differences on learning and retention, with eventual AD patients scoring lower than controls years prior to reporting symptoms of the disease. There was no significant interaction effect (group x testing session) for memory retention, suggesting that memory decline in this preclinical period may be too slow to be a useful indicator of future AD. A significant interaction (but no group effect) was seen for verbal comprehension.
- Published
- 2007
- Full Text
- View/download PDF
29. Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma.
- Author
-
Brown PD, Jensen AW, Felten SJ, Ballman KV, Schaefer PL, Jaeckle KA, Cerhan JH, and Buckner JC
- Subjects
- Adult, Astrocytoma mortality, Astrocytoma pathology, Brain Neoplasms mortality, Brain Neoplasms pathology, Cognition Disorders classification, Disease Progression, Female, Glioma mortality, Glioma pathology, Gliosarcoma mortality, Gliosarcoma pathology, Humans, Male, Middle Aged, Survival Rate, Astrocytoma complications, Brain Neoplasms complications, Cognition Disorders etiology, Glioma complications, Gliosarcoma complications
- Abstract
Purpose: There is growing recognition that the primary cause of cognitive deficits in adult patients with primary brain tumors is the tumor itself and more significantly, tumor progression. To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed., Patients and Methods: We studied 1,244 high-grade brain tumor patients entered onto eight consecutive North Central Cancer Treatment Group treatment trials that used radiation and nitrosourea-based chemotherapy. Imaging studies and Folstein Mini-Mental State Examination (MMSE) scores recorded at baseline, 6, 12, 18, and 24 months were analyzed to assess tumor status and cognitive function over time., Results: The proportion of patients without tumor progression who experienced clinically significant cognitive deterioration compared with baseline was stable at 6, 12, 18, and 24 months (18%, 16%, 14%, and 13%, respectively). In patients without radiographic evidence of progression, clinically significant deterioration in MMSE scores was a strong predictor of a more rapid time to tumor progression and death. At evaluations preceding interval radiographic evidence of progression, there was significant deterioration in MMSE scores for patients who were to experience progression, whereas the scores remained stable for the patients who did not have tumor progression., Conclusion: The proportion of high-grade glioma patients with cognitive deterioration over time is stable, most consistent with the constant pressure of tumor progression over time. Although other factors may contribute to cognitive decline, the predominant cause of cognitive decline seems to be subclinical tumor progression that precedes radiographic changes.
- Published
- 2006
- Full Text
- View/download PDF
30. Teaching motivational interviewing to first-year medical students to improve counseling skills in health behavior change.
- Author
-
Poirier MK, Clark MM, Cerhan JH, Pruthi S, Geda YE, and Dale LC
- Subjects
- Health Knowledge, Attitudes, Practice, Humans, Minnesota, Patient Education as Topic, Physician-Patient Relations, Surveys and Questionnaires, Counseling, Education, Medical methods, Health Behavior, Interviews as Topic, Motivation, Students, Medical
- Abstract
Objective: To examine the effectiveness of motivational interviewing training on improving medical students' knowledge of and confidence in their ability to counsel patients regarding health behavior change., Subjects and Methods: In the spring of 2002, 42 first-year medical students participated in a counseling course on health behavior change. Three small groups focused on learning and practicing motivational interviewing techniques using brief lectures, interactive class activities, student role-plays, and simulated patients. Students completed an identical precourse and postcourse questionnaire that measured their confidence and knowledge regarding counseling skills in health behavior change., Results: The medical students reported improved confidence in their understanding of motivational interviewing after participation in the course (very confident, 77%) compared with before the course (very confident, 2%). Each of the 8 confidence items were compared before and after the course using a signed rank test. All comparisons indicated a significant improvement (P < .001) in confidence. Regarding knowledge-based questions, students showed significant improvement; 31% of students answered all the questions correctly before the course, and 56% answered all the questions correctly after the course (P = .004)., Conclusion: These results show that teaching motivational interviewing techniques to first-year medical students can enhance student confidence in and knowledge of providing counseling to patients regarding health behavior change.
- Published
- 2004
- Full Text
- View/download PDF
31. Diagnostic utility of letter fluency, category fluency, and fluency difference scores in Alzheimer's disease.
- Author
-
Cerhan JH, Ivnik RJ, Smith GE, Tangalos EC, Petersen RC, and Boeve BF
- Subjects
- Adult, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Alzheimer Disease, Cognition Disorders diagnosis, Verbal Behavior
- Abstract
Word generation tasks, specifically letter fluency and category fluency, are a standard part of most test protocols used by clinical neuropsychologists to measure aspects of language and executive retrieval functions. Given the reliance on these measures as clinical tools, it is important to understand the diagnostic implications of patients' performances. In Alzheimer's disease (AD), category fluency has generally been found to be disproportionately impaired, whereas letter fluency is usually more mildly impaired. It has been proposed that this performance pattern occurs because access to temporal-lobe semantic stores is necessary for category fluency but not letter fluency. In this study, the diagnostic utility of category fluency, letter fluency, and difference scores (letter fluency minus category fluency) in AD were examined. Forty AD patients and 221 normal control subjects took category fluency and letter fluency tests. Traditional t-test comparisons revealed that the groups differed significantly on the two test tasks and in terms of mean difference scores. However, using sensitivity and specificity to calculate predictive values, only category fluency and letter fluency (but not difference scores) were useful in predicting AD in individuals. Furthermore, category fluency was superior to letter fluency in this regard. Likelihood ratio tables are provided for use in calculating the odds of AD for specific category fluency and letter fluency scores generated by individual patients.
- Published
- 2002
- Full Text
- View/download PDF
32. Understanding the diagnostic capabilities of cognitive tests.
- Author
-
Ivnik RJ, Smith GE, Cerhan JH, Boeve BF, Tangalos EG, and Petersen RC
- Subjects
- Aged, Alzheimer Disease psychology, Brain Damage, Chronic psychology, Female, Humans, Male, Middle Aged, Psychometrics, Reference Values, Reproducibility of Results, Alzheimer Disease diagnosis, Brain Damage, Chronic diagnosis, Neuropsychological Tests statistics & numerical data
- Abstract
Statistics (i.e., sensitivity, specificity, hit rates, positive and negative predictive values, odds ratios, and likelihood ratios) that best describe a diagnostic test's ability to classify persons as either "impaired" or "normal," but that are not commonly reported in neuropsychological research, are reviewed. These statistics are applied to Mayo Cognitive Factor Scale scores (MCFS; Smith et al., 1994) to demonstrate information that can be acquired about the diagnostic capabilities of cognitive tests as they are commonly used in clinical settings. Multivariate analyses then generated a statistical model that combines MCFS scores and improves on the diagnostic capabilities of the individual MCFS scores. This model enjoys better diagnostic power than individual scores. It establishes that cognitive testing that uses multiple measures is very good at differentiating normal from impaired cognitive states. Information is also provided that helps clinicians quantify a person's risk for cognitive impairment based on specific cognitive test score(s).
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.